$5.93
0.17% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US05153U1079
Symbol
AURA
Sector
Industry

Aura Biosciences Stock price

$5.93
+0.36 6.46% 1M
-2.82 32.23% 6M
-2.29 27.86% YTD
-1.17 16.48% 1Y
-11.09 65.16% 3Y
-8.87 59.93% 5Y
-8.87 59.93% 10Y
NYSE, Closing price Tue, May 20 2025
+0.01 0.17%
ISIN
US05153U1079
Symbol
AURA
Sector
Industry

Key metrics

Market capitalization $298.09m
Enterprise Value $188.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.33
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-102.84m
Free Cash Flow (TTM) Free Cash Flow $-80.06m
Cash position $127.99m
EPS (TTM) EPS $-1.90
P/E forward negative
Short interest 5.08%
Show more

Is Aura Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Aura Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aura Biosciences forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Aura Biosciences forecast:

Buy
100%

Financial data from Aura Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 1.21 1.21
9% 9%
-
-1.21 -1.21
9% 9%
-
- Selling and Administrative Expenses 21 21
20% 20%
-
- Research and Development Expense 80 80
17% 17%
-
-102 -102
17% 17%
-
- Depreciation and Amortization 1.21 1.21
9% 9%
-
EBIT (Operating Income) EBIT -103 -103
17% 17%
-
Net Profit -95 -95
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aura Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aura Biosciences Stock News

Neutral
GlobeNewsWire
6 days ago
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 s...
Neutral
GlobeNewsWire
6 days ago
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, ...
Neutral
GlobeNewsWire
6 days ago
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025
More Aura Biosciences News

Company Profile

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Head office United States
CEO Elisabet Pinos
Employees 106
Founded 2007
Website www.aurabiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today